Evidence map›Paper›PMID 19632318›Full record

ArticleCellular signalling2009

Regulation of protein kinase C delta downregulation by protein kinase C epsilon and mammalian target of rapamycin complex 2.

Alakananda Basu, Savitha Sridharan, Shalini Persaud

Abstract read
In one paragraph

Article in Cellular signalling, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Novel regulation of protein kinase C-η.Biochemical and biophysical research communications · 2012
    Article
  5. Frontier of epilepsy research - mTOR signaling pathway.Experimental & molecular medicine · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alakananda BasuDepartment of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA. abasu@hsc.unt.edu
Savitha Sridharan
Shalini Persaud
University of North Texas · USUniversity of North Texas Health Science Center · US

Funding

TUMOR NECROSIS FACTOR ALPHA SIGNALING IN BREAST CANCERR01CA071727 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BASU, ALAKANANDA · 1997 to 2009
$1.3M
NCI NIH HHS CA071727NCI NIH HHS R01 CA071727
6 · The paper itself

Abstract

Phosphorylation and dephosphorylation of PKCs can regulate their activity, stability and function. We have previously shown that downregulation of PKC delta by tumor promoting phorbol esters was compromised when HeLa cells acquired resistance to cisplatin (HeLa/CP). In the present study, we have used these cells to understand the mechanism of PKC delta downregulation. A brief treatment of HeLa cells with phorbol 12,13-dibutyrate (PDBu) induced phosphorylation of PKC delta at the activation loop (Thr505), turn motif (Ser643), hydrophobic motif (Ser662) and Tyr-311 sites to a greater extent in HeLa/CP cells compared to HeLa cells. Prolonged treatment with PDBu led to downregulation of PKC delta in HeLa but not in HeLa/CP cells. The PKC inhibitor Gö 6983 inhibited PDBu-induced downregulation of PKC delta, decreased Thr505 phosphorylation and increased PKC delta tyrosine phosphorylation at Tyr-311 site. However, knockdown of c-Abl, c-Src, Fyn and Lyn had little effect on PKC delta downregulation and Tyr311 phosphorylation. Pretreatment with the phosphatidylinositol 3-kinase inhibitor Ly294002 and mTOR inhibitor rapamycin restored the ability of PDBu to downregulate PKC delta in HeLa/CP cells. Knockdown of mTOR and rictor but not raptor facilitated PKC delta downregulation. Depletion of PKC epsilon also enhanced PKC delta downregulation by PDBu. These results suggest that downregulation of PKC delta is regulated by PKC epsilon and mammalian target of rapamycin complex 2 (mTORC2).

Indexed as

CarbazolesCell Line, TumorDown-RegulationDrug Resistance, NeoplasmGene Knockdown TechniquesHeLa CellsHumansIndolesMaleimidesPhorbol 12,13-DibutyratePhosphorylationProtein Kinase C-deltaProtein Kinase C-epsilonRNA, Small InterferingTranscription Factors2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimideCarbazolesCRTC2 protein, humanIndolesMaleimidesPhorbol 12,13-DibutyrateProtein Kinase C-deltaProtein Kinase C-epsilonRNA, Small InterferingTranscription Factors

Identifiers

PMID19632318
PMCPMC2748237
OpenAlexW2073622205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.